Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ACTRIMS 2023 | GFAP: a potential biomarker for progression in MS

Elias Sotirchos, MD, Johns Hopkins University School of Medicine, Baltimore, MD, discusses glial fibrillary acidic protein (GFAP) as an emerging biomarker for multiple sclerosis (MS). Research looking at GFAP is still in earlier stages compared to other MS biomarkers, such as neurofilament light chain (NfL). Still, studies have suggested that GFAP may be better associated with progression independent of relapses. Therefore, combining both biomarkers may better predict the disease course. However, other studies have not found similar findings, and the role of GFAP as a biomarker in MS remains under active investigation. This interview took place at the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum 2023 in San Diego, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.


Elias Sotirchos reports scientific advisory boards and/or consulting for Alexion, Viela Bio, Horizon Therapeutics, Genentech and Ad Scientiam; speaking honoraria from Alexion, Viela Bio and Biogen.